Thomas James Doyle net worth and biography

Thomas Doyle Biography and Net Worth

SVP, Finance and Accounting of Kura Oncology

Tom Doyle joined Kura in 2021 with more than 20 years of experience in the biotechnology, pharmaceutical and healthcare industries, leading finance teams from early-stage development through commercialization. Most recently, he was Vice President of Finance at Zogenix, Inc., supporting the clinical trials and launch of multiple therapies since 2013. Prior to Zogenix, Mr. Doyle was the Controller for Peregrine Pharmaceuticals, an oncology development and biomanufacturing company. He has also served as the Director of Revenue and Cost Accounting at ISTA Pharmaceuticals and the Director of Internal Audit and R&D Finance at Valeant Pharmaceuticals. Mr. Doyle is a certified public accountant and received his M.B.A. from California State University San Marcos and his Bachelor of Science in finance from San Diego State University.

What is Thomas James Doyle's net worth?: The estimated net worth of Thomas James Doyle is at least $1.56 million as of November 14th, 2025. Mr. Doyle owns 130,257 shares of Kura Oncology stock worth more than $1,560,479 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Doyle may own. Learn More about Thomas James Doyle's net worth.
How old is Thomas James Doyle?: Mr. Doyle is currently 53 years old. There are 4 older executives and no younger executives at Kura Oncology. The oldest executive at Kura Oncology is Ms. Kathleen Ford, Chief Operating Officer, who is 77 years old. Learn More on Thomas James Doyle's age.
How do I contact Thomas James Doyle?: The corporate mailing address for Mr. Doyle and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Thomas James Doyle's contact information.
Has Thomas James Doyle been buying or selling shares of Kura Oncology?: During the last quarter, Thomas James Doyle has sold $50,746.02 in Kura Oncology stock. Most recently, Thomas James Doyle sold 4,539 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a transaction totalling $50,746.02. Following the completion of the sale, the senior vice president now directly owns 130,257 shares of the company's stock, valued at $1,456,273.26. Learn More on Thomas James Doyle's trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Teresa Bair (Chief Legal Officer), Thomas Doyle (SVP, Finance and Accounting), Kathleen Ford (Chief Operating Officer), Laura Johnson (Director), Mollie Leoni (Chief Medical Officer), Thomas Malley (Director), Anthony Praill (CFO), Troy Wilson (President and Chief Executive Officer), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, Kura Oncology insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $410,000.00. In the last twelve months, insiders at the sold shares 16 times. They sold a total of 137,521 shares worth more than $1,308,039.69. The most recent insider tranaction occured on November, 14th when insider Teresa Brophy Bair sold 8,804 shares worth more than $98,428.72. Insiders at Kura Oncology own 6.4% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 11/14/2025.

Thomas James Doyle Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2025	Sell	4,539	$11.18	$50,746.02	130,257
9/29/2025	Sell	4,541	$8.94	$40,596.54	109,829
1/28/2025	Sell	4,949	$7.87	$38,948.63	88,193
1/29/2024	Sell	2,318	$17.80	$41,260.40	48,093
1/27/2023	Sell	1,548	$13.89	$21,501.72	16,841

Thomas James Doyle Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $11.98

$11.90

$12.32

50 Day Range

MA: $10.37

$8.85

$12.09

2 Week Range

Now: $11.98

$5.41

$12.49

Volume

1,438,355 shs

Average Volume

1,795,837 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Thomas Doyle Biography and Net Worth

What is Thomas James Doyle's net worth?

How old is Thomas James Doyle?

How do I contact Thomas James Doyle?

Has Thomas James Doyle been buying or selling shares of Kura Oncology?

Who are Kura Oncology's active insiders?

Are insiders buying or selling shares of Kura Oncology?